These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 7939775)

  • 1. Factor VIII inhibitor treatment. Immune tolerance.
    Nilsson IM
    Semin Hematol; 1994 Apr; 31(2 Suppl 4):44-8. PubMed ID: 7939775
    [No Abstract]   [Full Text] [Related]  

  • 2. The maintenance of tolerance after successful immune tolerance induction in hemophilia A and B: the North American Registry. Factor VIII/IX Subcommittee of the International Society for Thrombosis and Hemostasis.
    DiMichele D; Kroner B;
    Haematologica; 2000 Oct; 85(10 Suppl):40-2; discussion 42-4. PubMed ID: 11187869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex.
    Schimpf K; Schwarz P; Kunschak M
    Thromb Haemost; 1995 Mar; 73(3):553-5. PubMed ID: 7667845
    [No Abstract]   [Full Text] [Related]  

  • 4. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors.
    DiMichele DM; Kroner BL;
    Thromb Haemost; 2002 Jan; 87(1):52-7. PubMed ID: 11848456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemophilia factor VIII therapy. Immunological tolerance. A clinical perspective.
    White GC; Greenwood R; Escobar M; Frelinger JA
    Haematologica; 2000 Oct; 85(10 Suppl):113-6. PubMed ID: 11187862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hemophilia A with factor VIII inhibitor].
    Shima M
    Rinsho Ketsueki; 2003 Feb; 44(2):90-101. PubMed ID: 12692981
    [No Abstract]   [Full Text] [Related]  

  • 7. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.
    Hay CR; Brown S; Collins PW; Keeling DM; Liesner R
    Br J Haematol; 2006 Jun; 133(6):591-605. PubMed ID: 16704433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regimens of factor VIII administration--continuous infusion vs. bolus.
    Berntorp E
    Haematologica; 2000 Oct; 85(10 Suppl):69-71; discussion 71-2. PubMed ID: 11187875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunetolerance as treatment of alloantibodies to factor VIII in hemophilia. The International Registry of Immunetolerance Protocols.
    Mariani G; Scheibel E; Nogao T; Kasper CK; Ewing NP; Mauser-Bunschoten E; Ghirardini A; Bellocco R; Brackman HH
    Semin Hematol; 1994 Apr; 31(2 Suppl 4):62-4. PubMed ID: 7939781
    [No Abstract]   [Full Text] [Related]  

  • 10. [Prospective matched control study concerning the treatment and quality of life of hemophiliacs with inhibitors].
    Honda K; Nagao T; Kamiya T; Yoshioka A; Miyazaki T; Takeda T; Mori K; Fukutake K; Hanabusa H; Taki M; Mohri H; Miyama J; Takamatsu J; Kinoshita S; Shirahata A
    Rinsho Ketsueki; 1998 Jun; 39(6):416-21. PubMed ID: 9695668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibodies to factor VIII in hemophilia A patients.
    Brackmann HH; Schwaab R; Effenberger W; Hess L; Hanfland P; Oldenburg J
    Vox Sang; 2000; 78 Suppl 2():187-90. PubMed ID: 10938950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The German Registry of immune tolerance treatment in hemophilia--1999 update.
    Lenk H;
    Haematologica; 2000 Oct; 85(10 Suppl):45-7. PubMed ID: 11187870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy.
    Dimichele D
    Haemophilia; 2009 Jan; 15(1):320-8. PubMed ID: 18976249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitors in congenital coagulation disorders.
    Key NS
    Br J Haematol; 2004 Nov; 127(4):379-91. PubMed ID: 15521914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune tolerance in hemophilia and treatment of hemophiliacs with an inhibitor.
    Mariani G; Brackmann HH
    Haematologica; 2001 Mar; 86(3):225-6. PubMed ID: 11255267
    [No Abstract]   [Full Text] [Related]  

  • 16. Tolerance induction in hemophilia: innovation and accomplishments.
    Sherman A; Biswas M; Herzog RW
    Curr Opin Hematol; 2018 Sep; 25(5):365-372. PubMed ID: 29994897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immune disorders in hemophiliac patients].
    Kachorovskiĭ BV; Loginskiĭ VE; Vygovskaia IaI; Rudenko VP
    Ter Arkh; 1987; 59(10):81-5. PubMed ID: 3124282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune tolerance induction and the treatment of hemophilia. Malmö protocol update.
    Berntorp E; Astermark J; Carlborg E
    Haematologica; 2000 Oct; 85(10 Suppl):48-50; discussion 50-1. PubMed ID: 11187871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitors: resolving diagnostic and therapeutic dilemmas.
    Dimichele D
    Haemophilia; 2002 May; 8(3):280-7. PubMed ID: 12010424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
    Kubisz P; Plamenová I; Hollý P; Stasko J
    Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.